First-in-Human Clinical Feasibility Study of Ablation of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation
Thyroid® · 2025
DOI: 10.1177/10507256251372166 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Thyroid®, 2025. Verfasst von Stefano Spiezia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ospedale del Mare | ASLNA1 Centro Naples, Naples, Italy. Hauptthemen laut MEDLINE: Thyroid Nodule, Ablation Techniques. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Thyroid nodules are common in the general population, and most are benign. Thyroidectomy remains the most common treatment for symptomatic benign thyroid nodular disease. The objective of this study is to determine if a novel, cell-specific, nonthermal modality called nanosecond pulsed field ablation (nsPFA) can provide a safe and effective treatment for symptomatic thyroid nodules.
Methods
In this clinical feasibility trial (NCT06117085), an nsPFA percutaneous electrode was used to ablate benign thyroid nodules under ultrasound guidance. In Cohort 1 (5 patients), ablations were created during a thyroidectomy procedure (treat-and-resect), so that initial ablation zone characterization could be assessed histologically. In Cohort 2 (20 patients), up to 4 isolated ablations were created in the in situ thyroid for dose-ranging and to allow for estimation of ablation zone volume. In Cohort 3 (5 patients), the entire nodule was ablated with therapeutic intent using multiple, overlapping ablations for resolution of symptoms.
Results
For Cohort 1, the mean ablation zone measured 1.7 cm long by 0.7 cm wide post-ablation. For Cohort 2, the mean ablation zone was estimated to be 2.7 cc in volume at 90 days post-ablation (based on nodule size reduction from baseline). Transient dysphonia (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ospedale del Mare | ASLNA1 Centro Naples, Naples, Italy.
- Pulse Biosciences, Inc., Hayward, California, USA.
- Sarasota Memorial Hospital, Sarasota, Florida, USA.
ORCID-Profile: William A Knape
Zitieren
APA
Spiezia, S., Offi, C., Misso, C., Antonelli, G., Nuccitelli, R., Tufano, R. P., & Knape, W. A. (2025). First-in-Human Clinical Feasibility Study of Ablation of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation. Thyroid®. https://doi.org/10.1177/10507256251372166
Vancouver
Spiezia S, Offi C, Misso C, Antonelli G, Nuccitelli R, Tufano RP, et al. First-in-Human Clinical Feasibility Study of Ablation of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation. Thyroid®. 2025. doi:10.1177/10507256251372166
BibTeX
@article{Spiezia2025,
author = {Spiezia, Stefano and Offi, Chiara and Misso, Claudia and Antonelli, Giovanni and Nuccitelli, Richard and Tufano, Ralph P and Knape, William A},
title = {First-in-Human Clinical Feasibility Study of Ablation of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation},
journal = {Thyroid®},
year = {2025},
doi = {10.1177/10507256251372166}
}
EUVIMED